Novartis (NVS) In-Licenses Ophthalmic Drug From Lubris LLC
Zacks Investment Research | Apr 07, 2017 05:03AM ET
Novartis AG (NYSE:NVS) recently announced that it has exercised an option to in-license ECF843 for ophthalmic indications worldwide (outside Europe) from Lubris LLC.
A look at Novartis’ share price movement over the past one year shows that the stock has underperformed the Zacks classified Large Cap Pharma industry. Novartis’ stock decreased 1.9% during this period, while the industry gained 1.9%.
The company did not provide any financial details. The closing of the deal is subject to customary closing conditions that includes regulatory approvals.
We note that ECF843 is a recombinant human lubricin (rh-Lubricin) protein, developed by Lubris. ECF843 demonstrated the potential to provide immediate improvement of symptoms by increasing lubrication across various eye and tear surfaces as well as an improvement in signs of dry eye within 28 days without reporting treatment-related adverse events.
We note that Novartis has a diverse portfolio in ophthalmology and dry eye treatments with a global portfolio of artificial tear products that includes Systane, Tears Naturale and Genteal.
In Dec 2016, the company entered into a definitive agreement to acquire Encore Vision, Inc., a privately-held company focused on the development of a novel treatment for presbyopia to strengthen its ophthalmology portfolio. The transaction will add Encore Vision's lead candidate, EV06, a first-in-class disease modifying topical treatment for presbyopia to the company’s ophthalmology pipeline. Financial details of the transaction were, however, not disclosed.
We note that Novartis combined its retina medicines business with the Alcon pharmaceuticals business in 2016 which is now operating as one ophthalmology franchise under Novartis Pharmaceuticals.
The performance of the Alcon business has been disappointing due to lower surgical equipments sales owing to competition faced by intraocular lens and a slowdown in demand for equipment purchases. Novartis is mulling strategic options for Alcon which includes retaining the business to separation via a capital markets transaction such as a spin-off or an initial public offering.
We remind investors that Novartis broadened its oncology portfolio by acquiring GlaxoSmithKline plc’s (NYSE:GSK) certain oncology products and pipeline compounds in Mar 2015 after having divested its Animal Health Division to Eli Lilly and Company (NYSE:LLY) . In Oct 2015, it acquired a portfolio of cancer immunotherapies through the acquisition of Admune Therapeutics and added bispecific antibodies through a collaboration with Xencor, Inc. (NASDAQ:XNCR) in Jun 2016.
Get The News You Want
Going forward, we expect approval of new drugs and label expansion of existing ones to bode well for Novartis. Also, strong performance of growth products should be able to offset the impact of generic competition for Gleevec.
Novartis currently carries a Zacks Rank #4 (Sell). You can see .
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.